H-Glu-NPr2 | 118884-82-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: H-Glu-NPr2
• 英文别名: (4S)-4-amino-5-(dipropylamino)-5-oxopentanoic acid
• CAS: 118884-82-5
• 化学式: C₁₁H₂₂N₂O₃
• 分子量: 230.307
• InChiKey: GAHKFARBCMSAEI-VIFPVBQESA-N

物化性质

• 沸点：
  399.3±37.0 °C(Predicted)
• 密度：
  1.080±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  16
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  螺谷胺 、 H-Glu-NPr2 在 氯甲酸乙酯 、 三乙胺 作用下， 生成 (4S)-4-[[(4R)-5-(8-azaspiro[4.5]decan-8-yl)-4-[(3,5-dichlorobenzoyl)amino]-5-oxopentanoyl]amino]-5-(dipropylamino)-5-oxopentanoic acid
  参考文献：
  名称：

  Structure−Antigastrin Activity Relationships of New Spiroglumide Amido Acid Derivatives

  摘要：

  A series of new spiroglumide amido acid derivatives was synthesized and evaluated for their ability to inhibit the binding of cholecystokinin (CCK) to guinea pig brain cortex (CCKB receptors) and peripheral rat pancreatic acini (CCKA receptors), as well as to inhibit in vitro the gastrin-induced Ca2+ increase in rabbit gastric parietal cells. Appropriate chemical manipulations of the structure of spiroglumide (CR 2194), i.e., (R)-4-(3,5-dichlorobenzamido)-5-(8-azaspiro[4,5]decan-8-yl)-5-oxopentanoic acid, led to potent and selective antagonists of CCKB/gastrin receptors. Structure-activity relationships are discussed. Some of these new derivatives, as, for example, compound 54 (CR 2622), i.e., (S)-4-[[(R)-4'-[(3,5-dichlorobenzoyl)amino]-5'-(8-azaspiro[4.5] decan-8-yl)-5'-oxo-pentanonyl]amino]-5-(1-naphthylamino)-5- oxopentanoic acid, exhibit activity 70-170 times greater than that of spiroglumide, depending upon the model used (IC50 = 2 x 10(-8) vs 140 x 10(-8) mol in binding inhibition of [H-3]-N-Me-N-Leu-CCK-8 in guinea pig brain cortex and IC50 = 0.7 x 10(-8) vs 122.3 x 10(-8) mol in inhibition of gastrin-induced Ca2+ mobilization in parietal cells of rabbit, respectively). Computer-assisted conformational analysis studies were carried out in order to compare the chemical structure of both the agonist (pentagastrin) and the antagonist (54).

  DOI：

  10.1021/jm950372w
• 作为产物：
  描述：

  Z-Glu-NPr2 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以3.2 g的产率得到H-Glu-NPr2
  参考文献：
  名称：

  Synthesis and effect on gastric secretion of several di-or tripeptides related to proglumide.

  摘要：

  与普洛古米德（PhCO-DL-Glu-NPr2）相关的几种N-酰二肽或三肽被制备，并通过腹腔注射在大鼠身上检查其对胃分泌的影响。PhCOGlu（Phe-NH2）-NPr2、Z-Glu（Phe-NH2）-NPr2、PhCO-Glu（NPr2）-Phe-NH2和PhCO-Asp-(Phe-NH2)-NPr2抑制胃分泌，而PhCO-Glu（Asp-Phe-NH2）-NPr2则刺激胃分泌。在这些肽中，PhCO-Glu（Phe-NH2）-NPr2对胃分泌表现出最强的抑制活性，其效力超过普洛古米德。

  DOI：

  10.1248/cpb.36.3961

文献信息

• LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV
  申请人：GRAFFINITY PHARMACEUTICALS GMBH

  公开号：US20160009760A1

  公开（公告）日：2016-01-14

  The present invention relates to the use, for affinity purification of an antibody or an fragment of an antibody, of a ligand-substituted matrix comprising a support material and at least one ligand covalently bonded to the support material, the ligand being represented by formula (I) L-(Sp) v -Ar 1 —Am—Ar 2 (I) wherein L, SP, Ar 1 , AM, Ar 2 and v are defined herein.

  本发明涉及使用含有配体取代基质来亲和纯化抗体或抗体片段，所述基质包括支持材料和至少一个与支持材料共价结合的配体，所述配体由式(I)所表示：L-(Sp)v-Ar1—Am—Ar2(I)，其中L、SP、Ar1、AM、Ar2和v在此处有定义。
• Synthesis of N-acyl-.GAMMA.-D-glutamyl peptide derivatives containing a C-terminal small fragment of cholecystokinin and their effects on gastric secretion.
  作者：KOJI IUCHI、KEIZO ITO、GORO TSUKAMOTO

  DOI：10.1248/cpb.36.3433

  日期：——

  N-Acyl-γ-D-glutamyl peptide derivatives containing a C-terminal small fragment of cholecystokinin were prepared and their effects on gastric secretion were investigated. PhCO-D-Glu(Phe-NH2)-NPr2 and PhCO-D-Glu(Asp-Phe-NH2)-NPr2 inhibited gastric secretion, while PhCO-D-Glu(Met-Asp-Phe-NH2)-NPr2 and PhCO-D-Glu(Trp-Met-Asp-Phe-NH2)-NPr2 stimulated gastric secretion. The substitution of the acyl function at the N-terminal of PhCO-D-Glu(Phe-NH2)-NPr2 affected the activity. Z-D-Glu(Phe-NH2)-NPr2, 4-chlorobenzoyl-D-Glu-(Phe-NH2)-NPr2 and isonicotinoyl-D-Glu(Phe-NH2)-NPr2 were found to have more potent inhibitory activity against gastric secretion than proglumide (PhCO-DL-Glu-NPr2).

  制备了含有胆囊收缩素 C 端小片段的 N-酰基-γ-D-谷氨酰肽衍生物，并研究了它们对胃液分泌的影响。PhCO-D-Glu(Phe-NH2)-NPr2和PhCO-D-Glu(Asp-Phe-NH2)-NPr2抑制胃液分泌，而PhCO-D-Glu(Met-Asp-Phe-NH2)-NPr2和PhCO-D-Glu(Trp-Met-Asp-Phe-NH2)-NPr2刺激胃液分泌。PhCO-D-Glu(Phe-NH2)-NPr2 N 端酰基功能的替代影响了其活性。研究发现，Z-D-Glu(Phe-NH2)-NPr2、4-氯苯甲酰基-D-Glu-(Phe-NH2)-NPr2 和异烟酰基-D-Glu(Phe-NH2)-NPr2 对胃液分泌的抑制活性比丙谷胺（PhCO-DL-Glu-NPr2）更强。
• Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20050197350A1

  公开（公告）日：2005-09-08

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(I)，该化合物作为MCH受体拮抗剂。这些组合物在制药组合物中的应用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食症包括贪食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾等。
• GELLING AGENT
  申请人：Ajinomoto Co., Inc.

  公开号：EP2813558A1

  公开（公告）日：2014-12-17

  Provided is a gelling agent containing N-acyl acidic amino acid dialkylamide having a DL form ratio (D form/L form (weight/weight)) of 5/95 - 20/80 or 80/20 - 95/5, and using the gelling agent, a gel composition, particularly a rod-like gel composition, superior in transparency and strength, and superior in compatibility and spreadability when applied to the skin, hair and the like is provided.

  本发明提供了一种含有 N-酰基酸性氨基酸二烷基酰胺的胶凝剂，其 DL 形式比率（D 形式/L 形式（重量/重量））为 5/95 - 20/80 或 80/20 - 95/5，使用该胶凝剂可制成凝胶组合物，特别是棒状凝胶组合物，其透明度和强度更佳，涂抹于皮肤、头发等时的相容性和延展性也更佳。
• US20140341960A1
  申请人：——

  公开号：US20140341960A1

  公开（公告）日：2014-11-20